The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension

Clinical Biochemistry

Volumn 43, Issue 15, 2010, Pages 1212-1215

  Hou, Jianping ^a   Liang, Yonggang ^a   Gai, Xiaobo ^a   Zhang, Hueimin ^a   Yang, Xiangyue ^a   Lan, Xiaopeng ^a   Zheng, Weixing ^a   Huang, Mingfang ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; D dimer; Hypertension; P selectin; Von Willebrand factor

Indexed keywords

D DIMER; SELECTIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS;

ACUTE DISEASE; AGED; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; THROMBOSIS;

EID: 77956776881     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.07.013     Document Type: Article

References (29)

1. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
2. Hu D., Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 2008, 52:865-868.
3. Tsang T.S., Petty G.W., Barnes M.E., et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003, 42:93-100.
4. Wang J.G., Staessen J.A., Franklin S.S., Fagard R., Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005, 45:907-913.
5. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
6. Lip G.Y., Blann A.D. Endothelium and fibrinolysis in hypertension: important facets of a prothrombotic state?. Hypertension 2008, 52:218-219.
7. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009, 373:155-166.
8. Kinch J.W., Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. Arch Intern Med 1995, 155:1353-1360.
9. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:546S-592S.
10. Akar J.G., Jeske W., Wilber D.J. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008, 51:1790-1793.
11. Marin F., Roldan V., Climent V.E., et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 2004, 90:1162-1166.
12. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107:3141-3145.
13. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
14. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002, 106:1962-1967.
15. Roldan V., Marin F., Garcia-Herola A., Lip G.Y. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005, 116:321-325.
16. Nikitovic D., Zacharis E.A., Manios E.G., et al. Plasma levels of nitrites/nitrates in patients with chronic atrial fibrillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol 2002, 7:171-176.
17. Coll-Vinent B., Monteagudo J., Miro O., et al. Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thromb Res 2006, 117:235-240.
18. Freestone B., Chong A.Y., Nuttall S., Lip G.Y. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 2008, 122:85-90.
19. Varughese G.I., Patel J.V., Tomson J., Lip G.Y. Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation. Heart 2007, 93:495-499.
20. Michelson A.D., Barnard M.R., Hechtman H.B., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996, 93:11877-11882.
21. Blann A.D., Lip G.Y., Beevers D.G., McCollum C.N. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997, 77:1077-1080.
22. Kamath S., Blann A.D., Chin B.S., Lip G.Y. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 2003, 89:1093-1095.
23. Lip G.Y., Lip P.L., Zarifis J., et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996, 94:425-431.
24. Li-Saw-Hee F.L., Blann A.D., Lip G.Y. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000, 31:828-833.
25. Zeuthen E.L., Lassen J.F., Husted S.E. Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion. J Thromb Thrombolysis 2004, 17:185-189.
26. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003, 90:1163-1172.
27. Nozawa T., Inoue H., Hirai T., et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006, 109:59-65.
28. Giansante C., Fiotti N., Miccio M., Altamura N., Salvi R., Guarnieri G. Coagulation indicators in patients with paroxysmal atrial fibrillation: effects of electric and pharmacologic cardioversion. Am Heart J 2000, 140:423-429.
29. Stoddard M.F., Dawkins P.R., Prince C.R., Ammash N.M. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995, 25:452-459.